Navigation Links
FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
Date:3/22/2012

CHICAGO, March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the 61st Annual Scientific Sessions & Expo of the American College of Cardiology (ACC) in Chicago, March 24-27, Booth #15084. FirstMark will showcase the new cardiovascular test PREvent. PREvent is the first and only multiple biomarker blood test that accurately predicts near term (2-3 years) risk of myocardial infarction and death for coronary artery disease patients. PREvent is an exciting development in cardiovascular medicine, addressing the unmet need to access the risk of near term MI.

"The ACC's Scientific Sessions & Expo is one of the largest and most prestigious conferences attended by cardiologists. The meeting's focus on scientific innovation and clinical application in cardiology makes it a perfect venue for FirstMark to share the remarkable research data and benefits of PREvent. We are pleased to have this opportunity, and look forward to meeting with cardiologists attending the conference," said Thomas Silberg, President and CEO of GenWay Biotech.

PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal.  The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

Details about the test's research will be given in an oral research poster presentation at the conference, "An Aggregate of Pathway-Related Biomarkers Predict Risk of Acute Myocardial Infarction and Death," 9:30 a.m.-10:30 a.m., Sunday, March 25. (Session 1167 – Acute Coronary Syndromes: Clinical / McCormick Place South, Hall A, Poster Board: 117.) The abstract will be available following the presentation at FirstMarkPREvent.com.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit FirstMarkPREvent.com.

Media Contact: Deborah Moore of GenWay Biotech, +1-858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
2. Inaugural Meeting of the FirstMark Scientific Board of Advisors
3. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
4. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
5. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
6. Environmental Tectonics Corporation Exhibiting at the Annual Symposium on Advanced Wound Care and Wound Healing Society
7. Perry Baromedical Corporation Exhibiting at MEDICA 2008
8. More than half of Americans doubt US global leadership in 2020
9. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
10. Bioforce Receives American Botanical Councils Tyler Award
11. Herbal Microscopy Book Receives American Botanical Councils James A. Duke Book Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):